Implementing VTE Prevention in Ambulatory Cancer Care

Part of paid clinical trials in Burlington, Vermont.

Sponsor
University of Vermont
Study ID
NCT07292376
Status
Enrolling By Invitation

Conditions

  • Neoplasms
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clinical program — OTHER
    Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.

Study Details

assess effectiveness of a , compared with usual care, to assess The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question\[s\] it aims to answer are: Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program). Participant clinicians will be asked to * receive education about VTE prevention recommendations * carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.

Key Dates

Start date
Oct 1, 2025
Status verified
Dec 2025
Primary completion
Apr 30, 2026
Completion
Jul 30, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Clinical program

Primary Outcome Measure

Documented VTE risk assessment [ Time Frame: 30 days after new patient appointment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Vermont HealthBurlingtonVermont05405-

Find similar trials in Burlington, VT

Related Studies